Chapter 3 Interactions between the cell cycle and the myogenic program

Advances in Developmental Biology and Biochemistry

Volumn 11, Issue C, 2002, Pages 53-74

  Huang, Jing ^a   Thayer, Matt J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35848964851     PISSN: 15691799     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-1799(02)11003-3     Document Type: Review

References (134)

1. Andres V., and Walsh K. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol 132 (1996) 657-666
2. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., and Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281 (1998) 1674-1677
3. Barr F.G., Galili N., Holick J., Biegel J.A., Rovera G., and Emanuel B.S. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 3 (1993) 113-117
4. Benezra R., Davis R.L., Lockshon D., Turner D.L., and Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61 (1990) 49-59
5. Bischoff R. The satellite cell and muscle regeneration. In: Engel A.G., and Franzini-Armstrong C. (Eds). Myology (1994), McGraw-Hill, New York 97-133
6. Braun T., and Arnold H.H. Inactivation of Myf-6 and Myf-5 genes in mice leads to alterations in skeletal muscle development. Embo 14 (1995) 1176-1186
7. Braun T., Buschhausen-Denker G., Bober E., Tannich E., and Arnold H.H. A novel human muscle factor related to but distinct from MyoDl induces myogenic conversion in 10T1/2 fibroblasts. Embo J 8 (1989) 701-709
8. Buchkovich K., Duffy L.A., and Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58 (1989) 1097-1105
9. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., and Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 (1998) 1497-1501
10. Buyse I.M., Shao G., and Huang S. The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. Proc Natl Acad Sci USA 92 (1995) 4467-4471
11. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., and Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281 (1998) 1677-1679
12. Carey T.E., Worsham M.J., and Van-Dyke D.L. Chromosomal biomarkers in the clonal evolution of head and neck squamous neoplasia. J Cell Biochem Suppl (1993) 213-222
13. Cenciarelli C., De Santa F., Puri P.L., Mattei E., Ricci L., Bucci F., Felsani A., and Caruso M. Critical role played by cyclin D3 in the MyoD-mediated arrest of cell cycle during myoblast differentiation. Mol Cell Biol 19 (1999) 5203-5217
14. Chen J., Marechal V., and Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13 (1993) 4107-4114
15. Chen P.L., Scully P., Shew J.Y., Wang J.Y., and Lee W.H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58 (1989) 1193-1198
16. Cheng M., Sexl V., Sherr C.J., and Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 95 (1998) 1091-1096
17. Choi J., Costa M.L., Mermelstein C.S., Chagas C., Holtzer S., and Holtzer H. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc Natl Acad Sci USA 87 (1990) 7988-7992
18. Coppola J.A., Lewis B.A., and Cole M.D. Increased retinoblastoma gene expression is associated with late stages of differentiation in many different cell types. Oncogene 5 (1990) 1731-1733
19. Cox L.S., Midgley C.A., and Lane D.P. Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cells. Oncogene 9 (1994) 2951-2959
20. Davis R.J., D'Cruz C.M., Lovell M.A., Biegel J.A., and Barr F.G. Fusion of PAX7 to FKHR by the variant t(1;13) (p36;gl4) translocation in alveolar rhabdomyosarcoma. Cancer Res 54 (1994) 2869-2872
21. Davis R.L., Weintraub H., and Lassar A.B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51 (1987) 987-1000
22. DeCaprio J.A., Ludlow J.W., Lynch D., Furukawa Y., Griffin J., Piwnica-Worms H., Huang C.M., and Livingston D.M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58 (1989) 1085-1095
23. Dias P., Kumar P., Marsden H.B., Gattamaneni H.R., Heighway J., and Kumar S. N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int J Cancer 45 (1990) 593-596
24. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery Jr. C.A., Butel J.S., and Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
25. Dunaief J.L., Strober B.E., Guha S., Khavari P.A., Alin K., Luban J., Begemann M., Crabtree G.R., and Goff S.P. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell, cycle arrest. Cell 79 (1994) 119-130
26. Eckner R., Yao T.P., Oldread E., and Livingston D.M. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev 10 (1996) 2478-9240
27. Edmonson D.G., and Olson E.N. A gene with homology to the myc simulatory region of MyoDI is expressed during myogenesis and is sufficient to activate the muscle differentiation program. Genes Dev 3 (1989) 628-640
28. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinder K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
29. Elledge S.J. Cell cycle checkpoints: preventing an identity crisis. Science 274 (1996) 1664-1672
30. Elledge S.J., and Harper J.W. Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6 (1994) 847-852
31. Endo T., and Goto S. Retinoblastoma gene product Rb accumulates during myogenic differentiation and is deinduced by the expression of SV40 large T antigen. J Biochem (Tokyo) 112 (1992) 427-430
32. Endo T., and Nadal-Ginard B. Transcriptional and posttranscriptional control of c-myc during myogenesis:its mRNA remains inducible in differentiated cells and does not suppress the differentiated phenotype. Mol Cell Biol 6 (1986) 1412-1421
33. Ewen M.E., Slurs H.K., Sherr C.J., Matsushime H., Kato J., and Livingston D.M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73 (1993) 487-497
34. Fattaey A.R., Harlow E., and Helin K. Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes. Mol Cell Biol 13 (1993) 7267-7277
35. Fiddler T.A., Smith L., Tapscott S.J., and Thayer M.J. Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol Cell Biol 16 (1996) 5048-5057
36. Franklin D.S., and Xiong Y. Induction of pl8lNK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Mol Biol Cell 7 (1996) 1587-1599
37. Friedberg E.C., Walker G.C., and Siede W. DNA repair and mutagenesis. 2nd edition Edition (1995), ASM Press, Washington DC
38. Fu L., and Benchimol S. Participation of the human p53 3'UTR in translational repression and activation following gamma-irradiation. Embo J 16 (1997) 4117-4125
39. Gu W., Schneider J.W., Condorelli G., Kaushal S., Mahdavi V., and Nadal-Ginard B. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72 (1993) 309-324
40. Guo K., Wang J., Andres V., Smith R.C., and Walsh K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 15 (1995) 3823-3829
41. Haines D.S., Landers J.E., Engle L.J., and George D.L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 14 (1994) 1171-1178
42. Halevy O., Novitch B.G., Spicer D.B., Skapek S.X., Rhee J., Hannon G.J., Beach D., and Lassar A.B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267 (1995) 1018-1021 [see comments]
43. Hall P.A., McKee P.H., Menage H.D., Dover R., and Lane D.P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8 (1993) 203-207
44. Harper J.W., Adami G.R., Wei N., Keyomarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cipl is a potent inhibitor of GI cyclin-dependent kinases. Cell 75 (1993) 805-816
45. Harper J.W., and Elledge S.J. Cdk inhibitors in development and cancer. Curt Opin Genet Dev 6 (1996) 56-64
46. Harper J.W., Elledge S.J., Keyomarsi K., Dynlacht B., Tsai L.H., Zhang P., Dobrowolski S., Bai C., Connell-Crowley L., Swindell E., et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6 (1995) 387-400
47. Hasty P., Bradley A., Morris J.H., Edmondson D.G., Venuti J.M., Olson E.N., and Klein W.H. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature 364 (1993) 501-506 [see comments]
48. Hengst L., Gopfert U., Lashuel H.A., and Reed S.I. Complete inhibition of Cdk/cyclin by one molecule of p21(Cipl). Genes Dev 12 (1998) 3882-3888
49. Heselmeyer K., Schrock E., du-Manoir S., Blegen H., Shah K., Steinbeck R., Auer G., and Ried T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 93 (1996) 479-484
50. Jin Y., Mertens F., Mandahl N., Heim S., Olegard C., Wennerberg J., Biorklund A., and Mitelman F. Chromosome abnormalities in eighty-three head and neck squamous cell carcinomas: influence of culture conditions on karyotypic pattern. Cancer Res 53 (1993) 2140-2146
51. Kablar B., Krastel K., Ying C., Asakura A., Tapscott S.J., and Rudnicki M.A. MyoD and Myf-5 differentially regulate the development of limb versus trunk skeletal muscle. Development 124 (1997) 4729-4738
52. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., and Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51 (1991) 6304-6311
53. Kato J., Matsushime H., Hiebert S.W., Ewen M.E., and Sherr C.J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7 (1993) 331-342
54. Kiess M., Gill R.M., and Hamel P.A. Expression of the positive regulator of cell cycle progression, cyclin D3, is induced during differentiation of myoblasts into quiescent myotubes. Oncogene 10 (1995) 159-166
55. Kitzmann M., Vandromme M., Schaeffer V., Carac G., Labbe J.C., Lamb N., and Fernandez A. cdkl- and cdk2-mediated phosphorylation of MyoD Ser2110 in growing C2 myoblasts: role in modulating MyoD half-life and myogenic activity. Mol Cell Biol 19 (1999) 3167-3176
56. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev 10 (1996) 1054-1072
57. Konigsberg I.R., McElvain N., Tootle M., and Hermann H. The dissociability of deoxyribonucleic acid synthesis from the development of multimuclearity of muscle cells in culture. J Biophys Biochem Cytol 8 (1960) 333-343
58. Lai A., Marcellus R.C., Corbeil H.B., and Branton P.E. RBPI induces growth arrest by repression of E2F-dependent transcription. Oncogene 18 (1999) 2091-2100
59. Lee J.0., Russo A.A., and Pavletich N.P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391 (1998) 859-865
60. Lu X., and Lane D.P. Differential induction of transcriptionally active p53 following W or ionizing radiation: defects in chromosome instability syndromes?. Cell 75 (1993) 765-778
61. Maki C.G., and Howley P.M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 17 (1997) 355-363
62. Mal A., Chattopadhyay D., Ghosh M.K., Poon R.Y., Hunter T., and Harter M.L. p21 and retinoblastoma protein control the absence of DNA replication in terminally differentiated muscle cells. J Cell Biol 149 (2000) 281-292
63. Maltzman W., and Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4 (1984) 1689-1694
64. Martelli F., Cenciarelli C., Santarelli G., Polikar B., Felsani A., and Caruso M. MyoD induces retinoblastoma gene expression during myogenic differentiation. Oncogene 9 (1994) 3579-3790
65. Martin K., Trouche D., Hagemeier C., Sorensen T.S., La-Thangue N.B., and Kouzarides T. Stimulation of E2F1/DPl transcriptional activity by MDM2 oncoprotein. Nature 375 (1995) 691-694
66. Matsushime H., Roussel M.F., Matsushima K., Hishinuma A., and Sherr C.J. Cloning and expression of murine interleukin-1 receptor antagonist in macrophages stimulated by colony-stimulating factor 1. Blood 78 (1991) 616-623
67. Megeney L.A., Kablar B., Garrett K., Anderson J.E., and Rudnicki M.A. MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev 10 (1996) 1173-1183
68. Midgley C.A., Owens B., Briscoe C.V., Thomas D.B., Lane D.P., and Hall P.A. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 108 (1995) 1843-1848
69. Miller J.B. Myoblast diversity in skeletal myogenesis: how much and to what end?. Cell 69 (1992) 1-3 [comment]
70. Missero C., Di Cunto F., Kiyokawa H., Koff A., and Dotto G.P. The absence of p2lCip l/WAFI alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev 10 (1996) 3065-3075
71. Molkentin J.D., Black B.L., Martin J.F., and Olson E.N. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell 83 (1995) 1125-1136
72. Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
73. Morgan D.O. Principles of CDK regulation. Nature 374 (1995) 131-134
74. Mosner J., Mummenbrauer T., Bauer C., Sczakiel G., Grosse F., and Deppert W. Negative feedback regulation of wild-type p53 biosynthesis. Embo J 14 (1995) 4442-4449
75. Muller H., Lukas J., Schneider A., Warthoe P., Bartek J., Eilers M., and Strauss M. Cyclin DI expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 91 (1994) 2945-2949
76. Nabeshima Y., Hanaoka K., Hayasaka M., Esumi E., Li S., Nonaka I., and Nabeshima Y. Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 364 (1993) 532-535 [see comments]
77. Neuhold L.A., and Wold B. HLH forced dimers: tethering MyoD to E47 generates a dominant positive myogenic factor insulated from negative regulation by Id. Cell 74 (1993) 1033-1042
78. Newsham I., Claussen U., Ludecke H.J., Mason M., Senger G., Horsthemke B., and Cavenee W. Microdissection of chromosome band 11p15. 5: characterization of probes mapping distal to the HBBC locus. Genes Chromosom Cancer 3 (1991) 108-116
79. Novitch B.G., Mulligan G.J., Jacks T., and Lassar A.B. Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. J Cell Biol 135 (1996) 441-456
80. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein inhuman sarcomas. Nature 358 (1992) 80-83 [see comments]
81. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., and Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362 (1993) 857-860
82. Otten A.D., Firpo E.J., Gerber A.N., Brody L.L., Roberts J.M., and Tapscott S.J. Inactivation of MyoD-mediated expression of p2l in tumor cell lines. Cell Growth Differ 8 (1997) 1151-1160
83. Parker S.B., Eichele G., Zhang P., Rawls A., Sands A.T., Bradley A., Olson E.N., Harper J.W., and Elledge S.J. p53-independent expression of p21Cipl in muscle and other terminally differentiating cells. Science 267 (1995) 1024-1027 [see comments]
84. Patapoutian A., Yoon J.K., Miner J.H., Wang S., Stark K., and Wold B. Disruption of the mouse MRF4 gene identifies multiple waves of myogenesis in the myotome. Development 121 (1995) 3347-3358
85. Pestell R., Mani S., Wang C., Wu K., and Francis R. Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin Investig Drugs 9 (2000) 1849-1870
86. Price B.D., and Calderwood S.K. Increased sequence-specific p53-DNA binding activity after DNA damage is attenuated by phorbol esters. Oncogene 8 (1993) 3055-3062
87. Puri P.L., Avantaggiati M.L., Balsano C., Sang N., Graessmann A., Giordano A., and Levrero M. p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription. Embo J 16 (1997) 369-383
88. Rabbitts P., Bergh J., Douglas J., Collins F., and Waters J. A submicroscopic homozygous deletion at the D3S3 locus in a cell line isolated from a small cell lung carcinoma. Genes Chromosomes Cancer 2 (1990) 231-238
89. Rao P.H., Sreekantaiah C., Schantz S.P., and Chaganti R.S. Cytogenetic analysis of 11 squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet 77 (1994) 60-64
90. Rao S.S., Chu C., and Kohtz D.S. Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol 14 (1994) 5259-5267
91. Rao S.S., and Kohtz D.S. Positive and negative regulation of D-type cyclin expression in skeletal myoblasts by basic fibroblast growth factor and transforming growth factor beta. A role for cyclin D1 in control of myoblast differentiation. J Biol Chem 270 (1995) 4093-4100
92. Reifenberger G., Reifenberger J., Ichimura K., Meltzer P.S., and Collins V.P. Amplification of multiple genes from chromosomal region 12g13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54 (1994) 4299-4303
93. Rhodes S.J., and Konieczny S.F. Identification of MRF4: a new member of the muscle regulatory factor gene family. Genes Dev 3 (1989) 2050-2061
94. Ried T., Petersen L., Holtgreve-Grez H., Speicher M.R., Schrock E., du-Manoir S., and Cremer T. Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization. Cancer Res 54 (1994) 1801-1806
95. Riley D.J., Lee E.Y., and Lee W.H. The retinoblastoma protein: more than a tumor suppressor. Annu Rev Cell Biol 10 (1994) 1-29
96. Rudnicki M.A., Braun T., Hinuma S., and Jaenisch R. Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results is apparently normal muscle development. Cell 71 (1992) 383-390
97. Rudnicki M.A., Schnegelsberg P.N., Stead R.H., Braun T., Arnold H.H., and Jaenisch R. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 75 (1993) 1351-1359
98. Sanchez Y., and Elledge S.J. Stopped for repairs. Bioessays 17 (1995) 545-548
99. Sandhu C., and Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect Prev 24 (2000) 107-118 [In Process Citation]
100. Schneider J.W., Gu W., Zhu L., Mahdavi V., and Nadal-Ginard B. Reversal of terminal differentiation mediated by p107 in Rb-/- muscle cells. Science 264 (1994) 1467-1471
101. Scrable H.J., Johnson D.K., Rinchik E.M., and Cavenee W.K. Rhabdomyosarcoma-associated locus and MYOD1 are syntenic but separate loci on the short arm of human chromosome 11. Proc Natl Acad Sci USA 87 (1990) 2182-2186
102. Shapiro D.N., Sublett J.E., Li B., Downing J.R., and Naeve C.W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdornyosarcoma. Cancer Res 53 (1993) 5108-5112
103. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., and Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kipl. Genes Dev 11 (1997) 1464-1478
104. Sherr C.J. G1 phase progression: cycling on cue. Cell 79 (1994) 551-555 [see comments]
105. Sherr C.J., and Roberts J.M. Inhibitors of mammalian GI cyclin-dependent kinases. Genes Dev 9 (1995) 1149-1163
106. Sidle A., Palaty C., Dirks P., Wiggan O., Kiess M., Gill R.M., Wong A.K., and Hamel P.A. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mot Biol 31 (1996) 237-271
107. Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., and Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11 (1997) 3471-3481
108. Skapek S.X., Rhee J., Spicer D.B., and Lassar A.B. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267 (1995) 1022-1024 [see comments]
109. Slingerland J.M., and Pagano M. In: Pagano M. (Ed). Cell cycle control in higher eukaryotes (1997), Springer Verlag
110. Smith L., Liu S.J., Goodrich L., Jacobson D., Degnin C., Bentley N., Carr A., Flaggs G., Keegan K., Hoekstra M., and Thayer M.J. Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced GI arrest. Nature Genet. 19 (1998) 39-47
111. Song A., Wang Q., Goebl M.G., and Harrington M.A. Phosphorylation of nuclear MyOD is required for its rapid degradation. Mol Cell Biol 18 (1998) 4994-4999
112. Speicher M.R., Howe C., Crotty P., du-Manoir S., Costa J., and Ward D.C. Comparative genomic hybridization detects novel deletions and amplifications in head and neck squamous cell carcinomas. Cancer Res 55 (1995) 1010-1013
113. Stockdale F.E., and Holtzer H. DNA synthesis and myogenesis. Exp Cell Res 24 (1961) 508-520
114. Suijkerbuijk R.F., Olde-Weghuis D.E., Van-den-Berg M., Pedemour F., Forus A., Myklebost O., Glier C., Turc-Caret C., and Geurts-van-Kessel A. Comparative genomic hybridization as a tool to define two distinct chromosome 12-derived amplification units in well-differentiated liposarcomas. Genes Chromosomes Cancer 9 (1994) 292-295
115. Tajbakhsh S., Bober E., Babinet C., Pournin S., Arnold H., and Buckingham M. Gene targeting the myf-5 locus with nlacZ reveals expression of this myogenic factor in mature skeletal muscle fibres as well as early embryonic muscle. Dev Dyn 206 (1996) 291-300
116. Tajbakhsh S., Rocancourt D., and Buckingham M. Muscle progenitor cells failing to respond to positional cues adopt non- myogenic fates in myf-5 null mice. Nature 384 (1996) 266-270
117. Tapscott S.J., Thayer M.J., and Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 259 (1993) 1450-1453
118. Tevosian S.G., Shih H.H., Mendelson K.G., Sheppard K.A., Paulson K.E., and Yee A.S. HBPl: a HMG box transcriptional repressor that is targeted by the retinoblastoma family. Genes Dev 11 (1997) 383-396
119. Thorburn A.M., Walton P.A., and Feramisco J.R. MyoD induced cell cycle arrest is associated with increased nuclear affinity of the Rb protein. Mol Biol Cell 4 (1993) 705-713
120. Trouche D., Le Chalony C., Muchardt C., Yaniv M., and Kouzarides T. RB and hbrm cooperate to repress the activation functions of 132171. Proc Natl Acad Sci USA 94 (1997) 11268-11273
121. Wang J., and Walsh K. Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-dependent kinase 4 complex. Cell Growth Differ 7 (1996) 1471-1478
122. Wang J.Y., Knudsen E.S., and Welch P.J. The retinoblastoma tumor suppressor protein. Adv Cancer Res 64 (1994) 25-85
123. Waterman M.J., Stavridi E.S., Waterman J.L., and Halazonetis T.D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 19 (1998) 175-178
124. Weber-Hall S., Anderson J., McManus A., Abe S., Nojima T., Pinkerton R., Pritchard-Jones K., and Shipley J. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 56 (1996) 3220-3224
125. Welch P.J., and Wang J.Y. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75 (1993) 779-790
126. Willems A.R., Lanker S., Patton E.E., Craig K.L., Nason T.F., Mathias N., Kobayashi R., Wittenberg C., and Tyers M. Cdc53 targets phosphorylated G1 cyclins for degradation by the ubiquitin proteolytic pathway. Cell 86 (1996) 453-463
127. Wright W.E., Sassoon D.A., and Lin V.K. Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell 56 (1989) 607-617
128. Wu X., Bayle J.H., Olson D., and Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7 (1993) 1126-1132
129. Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., and Livingston D.M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375 (1995) 694-698
130. Xiong Y., Zhang H., and Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71 (1992) 505-514
131. Xiong Y., Zhang H., and Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7 (1993) 1572-1583
132. Zauberman A., Barak Y., ragimov N., levy N., and Oren M. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. Embo J 12 (1993) 2799-2808
133. Zhang J.M., Zhao X., Wei Q., and Paterson B.M. Direct inhibition of G(1) cdk kinase activity by MyoD promotes myoblast cell cycle withdrawal and terminal differentiation. Embo J 18 (1999) 6983-6993
134. Zhang W., Behringer R.R., and Olson E.N. Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. Genes Dev 9 (1995) 1388-1399